Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
Zarifa A, Lopez-Mattei J, Palaskas N, Iliescu C, Durand JB, Kim PY. Zarifa A, et al. Adv Exp Med Biol. 2020;1244:277-285. doi: 10.1007/978-3-030-41008-7_15. Adv Exp Med Biol. 2020. PMID: 32301022 Review.
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
Dev R, Zhong LL, Zarifa A, Albittar AA, Rubin L, Liu S, Yap TA, Dalal S, Hui D, Karp DD, Tsimberidou AM, Piha-Paul SA, Ahnert JR, Fu S, Meric-Bernstam F, Naing A. Dev R, et al. Among authors: zarifa a. Invest New Drugs. 2022 Feb;40(1):124-133. doi: 10.1007/s10637-021-01184-5. Epub 2021 Sep 24. Invest New Drugs. 2022. PMID: 34559346 Clinical Trial.
Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Zarifa A, Lopez-Mattei J, Palaskas NL, Iliescu C, Durand JB, Kim PY. Zarifa A, et al. Adv Exp Med Biol. 2021;1342:377-387. doi: 10.1007/978-3-030-79308-1_15. Adv Exp Med Biol. 2021. PMID: 34972975
Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study.
Sheshadri A, Goizueta AA, Shannon VR, London D, Garcia-Manero G, Kantarjian HM, Ravandi-Kashani F, Kadia TM, Konopleva MY, DiNardo CD, Pierce S, Zarifa A, Albittar AA, Zhong LL, Akhmedzhanov FO, Arain MH, Alfayez M, Alotaibi A, Altan M, Naing A, Mendoza TR, Godoy MCB, Shroff G, Kim ST, Faiz SA, Kontoyiannis DP, Khawaja F, Jennings K, Daver NG. Sheshadri A, et al. Among authors: zarifa a. Cancer. 2022 Jul 15;128(14):2736-2745. doi: 10.1002/cncr.34229. Epub 2022 Apr 22. Cancer. 2022. PMID: 35452134 Free PMC article.
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.
Altan M, Soto F, Zhong LL, Akhmedzhanov FO, Wilson NR, Zarifa A, Albittar AA, Yang V, Lewis J, Rinsurongkawong W, Jack Lee J, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Jennings K, Khawaja F, Faiz SA, Shannon VR, Shroff G, Godoy MCB, Daver NG, Gandhi S, Mendoza TR, Naing A, Daniel-MacDougall C, Heymach JV, Sheshadri A. Altan M, et al. Among authors: zarifa a. Oncologist. 2023 Nov 2;28(11):e1065-e1074. doi: 10.1093/oncolo/oyad118. Oncologist. 2023. PMID: 37156009 Free PMC article.
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma.
Gouda MA, Stephen B, Tian Y, Alshawa A, Onwugaje DOC, Albittar A, Yang Y, Zarifa A, Yilmaz B, Gurses S, Sprenger A, Derbala MH, Brink A, How JA, Moyers J, Piha-Paul SA, Hong DS, Meric-Bernstam F, Patel SP, Oliva IG. Gouda MA, et al. Among authors: zarifa a. J Immunother Precis Oncol. 2024 Nov 1;7(4):247-254. doi: 10.36401/JIPO-24-3. eCollection 2024 Nov. J Immunother Precis Oncol. 2024. PMID: 39524469 Free PMC article.
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Habra MA, et al. Among authors: zarifa a. J Immunother Cancer. 2019 Sep 18;7(1):253. doi: 10.1186/s40425-019-0722-x. J Immunother Cancer. 2019. PMID: 31533818 Free PMC article. Clinical Trial.
23 results